Evidence map›Paper›PMID 39571084›Full record

Observational studyRevista medica del Instituto Mexicano del Seguro Social2024

[Events attributable to Vaxzevria vaccine in pregnant women from a first-level hospital in Puebla].

Josafath Alan Huerta-Rojas, Gabriela Bravo-de la Rosa, Jesús Texis-Ramírez, Itari Teresa Reyes-Tobón

Abstract readObservational StudyEnglish Abstract
In one paragraph

Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Josafath Alan Huerta-RojasInstituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 55, Servicio de Medicina Familiar. Puebla, Puebla, México.ORCID 0000-0002-4936-4150
Gabriela Bravo-de la RosaInstituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 34. Servicio de Medicina Familiar. Puebla, Puebla, México.ORCID 0000-0002-2243-4673
Jesús Texis-RamírezInstituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 55, Servicio de Medicina Familiar. Puebla, Puebla, México.ORCID 0000-0002-8411-5627
Itari Teresa Reyes-TobónInstituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 55, Servicio de Medicina Familiar. Puebla, Puebla, México.ORCID 0000-0002-5677-6444

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: COVID-19 is a severe acute respiratory syndrome caused by SARS-CoV-2. This disease had a high mortality rate and turned into a pandemic, which is why it was considered a severe public health problem. In this context, pregnant patients were a vulnerable group and, consequently, an effective vaccine was necessary. Objective: To categorize the events attributable to the application of Vaxzevria vaccine in pregnant patients. Material and methods: Retrospective, cross-sectional, descriptive and observational study carried out at No. 55 Family Medicine Unit in Puebla, Puebla. 300 patients between 15 and 44 years of age who received the first dose of Vaxzevria vaccine were included. The Format of Notification of Events Presumably Attributable to Vaccination was reviewed. Results: The most representative general symptoms were headache in 44.3%; fever in 30.7%; asthenia and adynamia in 19.3%; adynamia in 19%, and limitation of movement in 3%. Concerning local symptoms and signs, 23% presented localized pain on the site where the vaccine was administered. Finally, regarding systemic symptoms, 21.7% had arthralgias and 20.7% myalgias. Conclusions: The symptoms and signs were of less severity for pregnant patients, and resolved in a few days, which is why it was safe the administration of Vaxzevria vaccine.

Indexed as

COVID-19COVID-19 VaccinesPregnancy Complications, InfectiousAdolescentAdultCross-Sectional StudiesFemaleHumansMexicoPregnancyRetrospective StudiesYoung AdultCOVID-19 VaccinesCOVID-19Drug-Related Side Effects and Adverse ReactionsOxford-AstraZeneca COVID Vaccine

Identifiers

PMID39571084
PMCPMC12408105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.